FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 440 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy... June 17, 2025 EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan July 13, 2023 How to Cope With Taking Long-Term Medication June 27, 2023 “The power of science”: HPV vaccine proven to dramatically reduce cervical... November 3, 2021 Load more HOT NEWS EMA Recommends Extension of Indications for Pirtobrutinib Oncology Research Rebounds from Pandemic Low, but Shows Cancer Patients Need... Can I Have a Non-Violent Relationship with Cancer (Part 2) From Scan to Scan: The Challenges of Living with Metastatic Cancer
